栽培条件对灵芝子实体的三萜组成及其活性的影响

以不同灵芝品种、不同栽培基质、不同管理方式、不同生长时期获得的灵芝子实体为原料,用95%乙醇超声提取,对提取物进行了含量测定、三萜组成分析和体外抗肿瘤实验。结果表明,不同子实体醇提物中三萜和甾醇类物质的含量在4.60-6.20mg/g之间;高效液相分析发现10种三萜化合物的种类和含量在样品间存在明显差异。所有灵芝子实体醇提物对肿瘤细胞L1210的增殖均有一定的抑制作用,开伞期的灵芝子实体醇提物抑制肿瘤增殖的活性优于其他生长时期。     

一种无孢灵芝菌丝体的活性成分

利用制备型高效液相、凝胶层析、制备型薄层色谱等方法对无孢灵芝龙芝2号的固体发酵菌丝体进行分离纯化,通过波谱分析,化合物分别鉴定为灵芝酸P（1）,灵芝酸T1（2）,灵芝酸Mk（3）,灵芝酸S（4）,灵芝酸T（5）,ganodermanondiol（6）,灵芝酸Me（7）,5α, 8α-epidioxyergosta-6, 22-dien-3β-ol（8）,灵芝酸R（9）,lanosta-7, 9(11), 24-trien-3α-hydroxy-26-oic acid（10）,ganodermenonol（11）。其中灵芝酸T1为首次发现的天然产物。体外细胞实验证实,11种化合物对肿瘤细胞L1210的增殖均有很强的抑制作用,其增殖抑制的IC₅₀值均在39.69μmol/L以下。     

漆酶同工酶基因在斑玉蕈生长发育过程中的表达分析

为了探明漆酶在斑玉蕈生长发育过程中的功能,对斑玉蕈转录测序预测的13个漆酶基因序列进行分析、鉴定和构建分子系统发育树;检测了不同生长发育时期漆酶的活性和漆酶基因表达水平。研究结果显示：13个基因片段中有10个是漆酶基因。不同的漆酶同工酶之间进化关系存在明显差异,大多数漆酶与木腐菌（金针菇Flammulina filiformis和侧耳属Pleurotus）进化关系较近。对斑玉蕈不同生长发育时期的酶活检测结果显示,从斑玉蕈的菌丝恢复期到钉头期,漆酶活性逐渐升高,而在子实体形成后期酶活逐渐降低。对培养40d、60d和80d的菌丝样品以及不同生长发育时期的样品进RT-qPCR检测,结果显示在菌丝营养生长时期,大多数漆酶基因在第40-60天表达量持续增加1-3倍,而在第60-80天时表达量出现降低的情况。而在生殖生长时期,大多数漆酶基因在转色期或者原基期相对表达量达到最大值,并在子实体期出现降低,这与漆酶活性的检测具有一致性。lcc3、lcc7、lcc8和lcc9在斑玉蕈生殖生长过程中相对表达量出现了10-100倍的上调。这说明从菌丝培养到菌丝扭结形成子实体和子实体发育的过程中,不同的漆酶可能发挥着不同的作用,表达量较高的漆酶基因可能对基质降解和子实体形成起主要作用。     

野生田头菇菌株的驯化及其子实体营养成分分析

采自湖南洞庭湖大通湖区芦苇湿地的野生菌株,经鉴定为田头菇Agrocybe praecox。通过驯化实现人工栽培,栽培原料以芦苇屑为主,使用液体菌种和覆土栽培方式,初潮菇平均生物转化率为45.6%。营养成分分析表明：以芦苇屑为栽培培养基,子实体中矿物元素含量分别为K（2 190mg/kg）、Fe（16.2mg/kg）、Mg（59.7mg/kg）、Ca（33.4mg/kg）,必需氨基酸含量占比高达44.85%,谷氨酸、蛋氨酸、天冬氨酸含量高,是一种高蛋白、低脂肪、高钾低钠的食用菌。     

福廷瓶头霉与马尾松的共生特征

深色有隔内生真菌（dark septate endophyte,DSE）广泛定殖于植物根系,对促进植物生长、提高植物抗逆能力具重要作用。本研究从马尾松Pinus massoniana根系分离到一株DSE,于无菌条件下研究了此菌与马尾松的共生特征,研究结果表明：基于形态学和分子生物学分析,此菌被鉴定为福廷瓶头霉Phialocephala fortinii,在PDA培养基25℃培养条件下,此菌不产孢,菌丝深色、具隔,最适培养基为PDA。此菌与马尾松根系共生体的形成过程可划分为3个时期,即侵入前期：接种后2d,新生菌丝向马尾松根系定向生长并开始接触根系,但未侵入根系内部;侵入期：接种后4d,菌丝与马尾松根系接触侵入根内并在根系皮层细胞间扩展延伸;形成期：接种后6d,菌丝继续在马尾松根系内扩展并形成富含脂类物质的微菌核。接种福廷瓶头霉显著增加了马尾松生物量的积累（P<0.05）,并影响了其根系发育。接种后,马尾松主根生长受限,侧根生长显著提高（P<0.05）,侧根长度较未接种处理增加了112.87%。被侵染根系的根毛数量减少,并由大量根外菌丝包裹。以上结果对进一步揭示DSE与宿主的共生机理有一定指导意义。     

Tumour‐derived exosomal miR‐3473b promotes lung tumour cell intrapulmonary colonization by activating the nuclear factor‐κB of local fibroblasts

Tumour‐derived exosomes have been shown to induce pre‐metastatic niche formation, favoring metastatic colonization of tumour cells, but the underlying molecular mechanism is still not fully understood. In this study, we showed that exosomes derived from the LLC cells could indeed significantly enhance their intrapulmonary colonization. Circulating LLC‐derived exosomes were mainly engulfed by lung fibroblasts and led to the NF‐κB signalling activation. Further studies indicated that the exosomal miR‐3473b was responsible for that by hindering the NFKB inhibitor delta's (NFKBID) function. Blocking miR‐3473b could reverse the exosome‐mediated NF‐κB activation of fibroblasts and decrease intrapulmonary colonization of lung tumour cells. Together, this study demonstrated that the miR‐3473b in exosomes could mediate the interaction of lung tumour cells and local fibroblasts in metastatic sites and, therefore, enhance the metastasis of lung tumour cells.     

Sirtuin 5 regulates the proliferation,invasion and migration of prostate cancer cells through acetyl‐CoA acetyltransferase 1

Sirtuin 5 (SIRT5) is a NAD⁺‐dependent class III protein deacetylase, and its role in prostate cancer has not yet been reported. Therefore, to explore the diagnosis and treatment of prostate cancer, we investigated the effect of SIRT5 on prostate cancer. Sirtuin 5 was assessed by immunohistochemistry in 57 normal and cancerous prostate tissues. We found that the tissue expression levels of SIRT5 in patients with Gleason scores ≥7 were significantly different from those in patients with Gleason scores <7 (P < .05, R > 0). Further, mass spectrometry and pathway screening experiments showed that SIRT5 regulated the activity of the mitogen‐activated protein kinase (MAPK) pathway, which in turn modulated the expression of MMP9 and cyclin D1. Being a substrate of SIRT5, acetyl‐CoA acetyltransferase 1 (ACAT1) was regulated by SIRT5. SIRT5 also regulated MAPK pathway activity through ACAT1. These results revealed that SIRT5 promoted the activity of the MAPK pathway through ACAT1, increasing the ability of prostate cancer cells to proliferate, migrate and invade. Overall, these results indicate that SIRT5 expression is closely associated with prostate cancer progression. Understanding the underlying mechanism may provide new targets and methods for the diagnosis and treatment of the disease.     

Aldosterone enhances high phosphate–induced vascular calcification through inhibition of AMPK‐mediated autophagy

It remains unclear whether the necessity of calcified mellitus induced by high inorganic phosphate (Pi) is required and the roles of autophagy plays in aldosterone (Aldo)‐enhanced vascular calcification (VC) and vascular smooth muscle cell (VSMC) osteogenic differentiation. In the present study, we found that Aldo enhanced VC both in vivo and in vitro only in the presence of high Pi, alongside with increased expression of VSMC osteogenic proteins (BMP2, Runx2 and OCN) and decreased expression of VSMC contractile proteins (α‐SMA, SM22α and smoothelin). However, these effects were blocked by mineralocorticoid receptor inhibitor, spironolactone. In addition, the stimulatory effects of Aldo on VSMC calcification were further accelerated by the autophagy inhibitor, 3‐MA, and were counteracted by the autophagy inducer, rapamycin. Moreover, inhibiting adenosine monophosphate‐activated protein kinase (AMPK) by Compound C attenuated Aldo/MR‐enhanced VC. These results suggested that Aldo facilitates high Pi‐induced VSMC osteogenic phenotypic switch and calcification through MR‐mediated signalling pathways that involve AMPK‐dependent autophagy, which provided new insights into Aldo excess‐associated VC in various settings.     

Gilteritinib induces PUMA‐dependent apoptotic cell death via AKT/GSK‐3β/NF‐κB pathway in colorectal cancer cells

As a highly potent and highly selective oral inhibitor of FLT3/AXL, gilteritinib showed activity against FLT3D835 and FLT3‐ITD mutations in pre‐clinical testing, although its role on colorectal cancer (CRC) cells is not yet fully elucidated. We examined the activity of gilteritinib in suppressing growth of CRC and its enhancing effect on other drugs used in chemotherapy. In this study, we observed that, regardless of p53 status, treatment using gilteritinib induces PUMA in CRC cells via the NF‐κB pathway after inhibition of AKT and activation of glycogen synthase kinase 3β (GSK‐3β). PUMA was observed to be vital for apoptosis in CRC cells through treatment of gilteritinib. Moreover, enhancing induction of PUMA through different pathways could mediate chemosensitization by using gilteritinib. Furthermore, PUMA deficiency revoked the antitumour role of gilteritinib in vivo. Thus, our results indicate that PUMA mediates the antitumour activity of gilteritinib in CRC cells. These observations are critical for the therapeutic role of gilteritinib in CRC.